Mustang Bio, Inc.
(NASDAQ : MBIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
-2.02%34.370.9%$1160.45m
JNJJohnson & Johnson
-2.61%127.840.7%$889.28m
MRKMerck & Co., Inc.
-2.00%84.990.6%$770.60m
BMYBristol-Myers Squibb Company
-2.63%46.601.4%$625.84m
ABBVAbbVie, Inc.
-2.24%66.012.3%$624.11m
LLYEli Lilly and Company
-1.85%109.551.0%$414.75m
NVSNovartis AG Sponsored ADR
-0.63%88.440.2%$173.85m
AZNAstraZeneca PLC Sponsored ADR
-1.81%44.591.2%$172.00m
GSKGlaxoSmithKline plc Sponsored ADR
0.56%41.210.3%$98.85m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.85%52.250.1%$73.51m
SNYSanofi Sponsored ADR
0.02%42.580.2%$46.98m
LCILannett Company, Inc.
-5.98%6.4536.6%$4.37m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.81%1.731.6%$3.33m
EPIXESSA Pharma Inc
22.22%2.200.1%$0.09m

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.